WOODCLIFF LAKE, N.J., April 15 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that the U.S. District Court for the District of Delaware has ruled in favor of Par in its challenge of the University of Missouri’s patents relating to omeprazole/sodium bicarbonate capsules (20 mg/1.1 g and 40 mg/1.1 g) and powders for oral suspension (20 mg/1.68 g and 40 mg/1.68 g), which are listed in the Orange Book for Santarus’s Zegerid(R) product. Par earlier announced that it had filed an ANDA seeking marketing approval for generic omeprazole/sodium bicarbonate capsules and powders for oral suspension, and that it was the first-filed ANDA with respect to the Zegerid product.
About Par Pharmaceutical Companies, Inc.
Safe Harbor Statement
CONTACT: Allison Wey, Par Pharmaceutical Companies, Inc., +1-201-802-4000
Web site: http://www.parpharm.com/
